Major Deal Pushes Parkinson's Vaccine Further in Testing

I just got an email from The Michael J. Fox Foundation (MJFF).

"

Dear Friend,

A long-watched Parkinson’s therapy supported by The Michael J. Fox Foundation (MJFF) just got a significant jumpstart. A major deal with another Foundation grantee is pushing the Parkinson’s vaccine closer to patient hands.

Between 2010 and 2015 MJFF provided funding to biotech AFFiRiS for development and testing of its vaccine, PD01. The therapy prompts the body to produce antibodies against the protein alpha-synuclein, known to form harmful clumps in the cells of people with Parkinson’s.

This month, AC Immune acquired the AFFiRiS alpha-synuclein portfolio and will now advance an optimized version of the vaccine into a Phase II trial. MJFF has also funded AC Immune to develop key tools to measure alpha-synuclein, which could speed testing of this and other therapies.

This hand-off is a textbook example of our de-risking strategy: MJFF supports early, risky projects to help build data that will attract partners who can usher them through larger, more expensive later-stage trials. We also fund research toward better tools to de-risk investments and accelerate new treatments.

DONATE

With your help, we can continue to fund high-impact research that accelerates promising ideas toward real solutions for people with Parkinson’s. Please donate today to keep critical projects moving forward as quickly as possible."

[Dap1948]

Isn’t this what mannitol does? jbc.org/article/S0021-9258(...

[gginto]

I got this too- Looks promising!

[PwPKaren]

what does this mean to people with PD????

[Hidden in reply to PwPKaren]

That we wait but with another reason for hope

[Discogs_discogs]

Did they mention whether we could sign up for a clinical trial of this new vaccine or not?